6533b856fe1ef96bd12b25d3
RESEARCH PRODUCT
P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer
Liang ShenDaniel Virgil Thomas CatenacciMarkus MoehlerHarry H. YoonH.c. ChungY. KangM. Koshiji Rosalessubject
OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologymedicine.diseaseGastroesophageal JunctionFirst line therapyOncologyInternal medicinemedicinebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2021-07-01 | Annals of Oncology |